VAUGHAN, Ontario, January 07, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

Save 23% on what we rate as one of the best telescopes out there. It features a 102mm aperture, a 1325mm focal length, a Maksutov-Cassegrain optical design, smartphone-controlled and it comes with ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial ...

City Therapeutics, Inc. set to collaborate with Bausch + Lomb on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA). The arrangement of this ...

Bausch + Lomb acquired Whitecap Biosciences to develop therapies for glaucoma and geographic atrophy, aiming to improve visual outcomes. Whitecap's WB007, an alpha-2 adrenergic agonist, showed IOP ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

City Therapeutics will develop an RNAi clinical candidate for intravitreal administration targeting retinal diseases, including geographic atrophy. Bausch + Lomb will manage IND-enabling studies, ...

The collaboration may expand into other ocular conditions. Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age ...